All In Biotech

Drug Trial Radar · NCT00005970

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,436 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,436

Actual

Start

May 19, 2000

Primary completion

Apr 25, 2005

Study completion Jan 27, 2010

Sponsor

Sponsor type
NIH
Collaborators
Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; SWOG Cancer Research Network
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer.

Conditions

  • Breast Adenocarcinoma
  • HER2 Positive Breast Carcinoma
  • Stage IA Breast Cancer AJCC v7
  • Stage IB Breast Cancer AJCC v7
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage IIIA Breast Cancer AJCC v7

Interventions

  • Aromatase Inhibition TherapyDrug

    Given orally

  • CyclophosphamideDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • Tamoxifen CitrateDrug

    Given orally

  • TrastuzumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of DFSTime frame: Time from registration to first adverse event, assessed up to 15 years

Locations

157 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Western Regional CCOP

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Community Cancer Institute

    Clovis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Washington Hospital

    Fremont, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Salinas Valley Memorial

    Salinas, California

  • University of California San Diego

    San Diego, California

  • Naval Medical Center -San Diego

    San Diego, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • The Angeles Clinic and Research Institute - Santa Monica Office

    Santa Monica, California

  • Santa Rosa Memorial Hospital

    Santa Rosa, California

  • University of Colorado Hospital

    Aurora, Colorado

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Atlanta Regional CCOP

    Atlanta, Georgia

  • Northeast Georgia Medical Center-Gainesville

    Gainesville, Georgia

  • Memorial Health University Medical Center

    Savannah, Georgia

  • University of Hawaii Cancer Center

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Illinois

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Heartland Cancer Research NCORP

    Decatur, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Northern Indiana Cancer Research Consortium

    South Bend, Indiana

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.